Susquehanna International Group, LLP Celldex Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $67,326 - $93,576	2,100 Added 2.02%	106,000 $3.6 Million
Q2 2024 Aug 15, 2024	SELL	$32.76 - $42.56 $1.57 Million - $2.04 Million	-47,900 Reduced 31.55%	103,900 $3.85 Million
Q1 2024 May 07, 2024	BUY	$35.22 - $51.88 $1.06 Million - $1.57 Million	30,200 Added 24.84%	151,800 $6.37 Million
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $94,962 - $170,730	-4,200 Reduced 3.34%	121,600 $4.82 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $1.56 Million - $2.3 Million	61,400 Added 95.34%	125,800 $3.46 Million
Q2 2023 Aug 11, 2023	SELL	$30.29 - $38.28 $39,377 - $49,764	-1,300 Reduced 1.98%	64,400 $2.19 Million
Q1 2023 May 16, 2023	SELL	$34.78 - $47.43 $2.89 Million - $3.94 Million	-83,100 Reduced 55.85%	65,700 $2.36 Million
Q4 2022 Feb 14, 2023	SELL	$27.78 - $45.38 $13,890 - $22,690	-500 Reduced 0.33%	148,800 $6.63 Million
Q3 2022 Nov 14, 2022	SELL	$22.7 - $37.57 $1.61 Million - $2.67 Million	-71,100 Reduced 32.26%	149,300 $4.2 Million

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.23B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.